Track AEON and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
AEON Biopharma, Inc.
5 Park Plaza, Irvine, CA, United States, 92614
IPO
2021
Employees
8
Industry
Biotechnology
Sector
Healthcare
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 20250+2
2
Analyst Ratings
No coverage data
No analyst ratings data available